2 In our clinical experience, approximately 20% of patients with moderate-to-severe psoriasis are currently treated with anti-TNF agents including etanercept, infliximab and adalimumab.

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars market Opportunities and Strategies to 2033" report ...

Patients enrolled onto the German biologics register (RABBIT; etanercept n = 512, infliximab n = 346, DMARD control n = 601) have been studied, and the relative risk of serious infections was 2.2 ...

For etanercept, following an initial dose of 50 mg twice weekly, the dose was reduced to 25 mg twice weekly for the remainder of the year. [18] For infliximab, initial dosing occurred at 0 ...

Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, ...